Scarica l'app Stockscreener
1.38
2.13%
-0.03
Dopo l'orario di chiusura:
1.39
0.01
+0.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Ocugen Inc Borsa (OCGN) Ultime notizie
Ocugen stock dips as Q1 losses widen - MSN
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Price Target Cut to $11.00/Share From $12.00 by Canaccord Genuity - Moomoo
OCGN Maintained by Canaccord Genuity -- Price Target Lowered to $11 - GuruFocus
Three Speculative Biotech Penny Stocks With Pipeline Catalysts - Kalkine Media
Ocugen Is Maintained at Buy by Canaccord Genuity - Moomoo
Canaccord lowers Ocugen stock price target to $11 on model update By Investing.com - Investing.com South Africa
Canaccord lowers Ocugen stock price target to $11 on model update - Investing.com
CCORF Maintains Ocugen(OCGN.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
FTSE Russell Index Reconstitution Sees Major Changes with Ocugen (OCGN) Joining - GuruFocus
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Ocugen (OCGN) Set for Inclusion in Russell 3000 Index Rebalancin - GuruFocus
OCGN Stock Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Q4 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Inc stock (US67577C1053): FDA feedback keeps retinitis pigmentosa trial on track - AD HOC NEWS
Stock Quote & Chart - Ocugen, Inc.
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen closes $130 million convertible notes offering - Investing.com UK
Gene therapy pipeline accelerates as Ocugen, Inc. targets approvals for RP and Stargardt disease - Traders Union
Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout
Ocugen Raises $130 Million Through Convertible Notes Offering - TipRanks
Ocugen Announces Interim Chief Medical Officer Appointment Transition - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes - Ocugen, Inc.
Ocugen closes $130 million convertible notes offering By Investing.com - Investing.com Australia
Ocugen Reports Positive GA Trial Data, Extends Cash Runway - MyChesCo
Ocugen (NASDAQ: OCGN) shifts CMO duties to interim leader - Stock Titan
Ocugen (NASDAQ: OCGN) closes $130M 6.75% convertible notes due 2034 - Stock Titan
Ocugen signs license deal with Korean company for gene therapy - MSN
Ocugen issues $115M notes to repay debt; stock faces after-hours selling - MSN
Ocugen to Participate in Upcoming May Scientific and Investor Conferences - Sahm
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally - The Motley Fool
Ocugen’s Convertible Cash and Reverse Split Vote Set the Table for a Triple-Data Summer - AD HOC NEWS
Ocugen, Inc. to Present Innovative Modifier Gene Therapy Platform at May 2026 Conferences - Quiver Quantitative
Ocugen brings blindness gene therapy to two May events in 2026 - Stock Titan
Ocugen (OCGN) Reports Q1 EPS - Insider Monkey
Ocugen’s Clinical Calendar Packs a Punch in Q3 as Analysts Stay Bullish on Gene Therapy Pipeline - AD HOC NEWS
5 Best Penny Stocks to Buy Before They Explode - Insider Monkey
Ocugen stock (US67577C1053): Q1 2026 earnings miss sparks stock drop - AD HOC NEWS
Ocugen, Inc. advances automation in quantitative autofluorescence for geographic atrophy at ARVO2026 - Traders Union
0.37%
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):